Vericel (VCEL) Gains from Investment Securities (2012 - 2018)
Vericel (VCEL) posted Gains from Investment Securities of -$420000.0 for Q3 2018, down 1235.14% sequentially from $37000.0 in Q2 2018, and down 139.62% YoY from $1.1 million in Q3 2017.
Powered by 
Analysis
Vericel (VCEL) Gains from Investment Securities (2012 - 2018) Analysis & Trends
Vericel has reported Gains from Investment Securities for 7 years, with the latest figure at -$420000.0 in Q3 2018.
- Quarterly Gains from Investment Securities fell 139.62% year-over-year to -$420000.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was -$420000.0 (down 111.2% YoY) and the FY2018 annual result came in at $2.5 million, up 882.1% from the prior year.
- Gains from Investment Securities eased to -$420000.0 in Q3 2018 per VCEL's latest filing, from $37000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.9 million in Q1 2018 and troughed at -$1.9 million in Q2 2016.
- A 5-year average of $130736.8 and a median of -$107000.0 in 2017 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2016 and 2018: Gains from Investment Securities plunged 1633.93% in 2016, then surged 2816.82% in 2018.
- Over 5 years, Gains from Investment Securities stood at -$128000.0 in 2014, then surged by 46.88% to -$68000.0 in 2015, then soared by 245.59% to $99000.0 in 2016, then slumped by 357.58% to -$255000.0 in 2017, then plunged by 64.71% to -$420000.0 in 2018.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$420000.0, $37000.0, and $2.9 million for Q3 2018, Q2 2018, and Q1 2018 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | -420,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 2.91 Mn |
| Dec 31, 2017 | -255,000.00 |
| Sep 30, 2017 | 1.06 Mn |
| Jun 30, 2017 | -441,000.00 |
| Mar 31, 2017 | -107,000.00 |
| Dec 31, 2016 | 99,000.00 |
| Sep 30, 2016 | 203,000.00 |
| Jun 30, 2016 | -1.94 Mn |
| Mar 31, 2016 | 1.64 Mn |
| Dec 31, 2015 | -68,000.00 |
| Sep 30, 2015 | -461,000.00 |
| Jun 30, 2015 | -112,000.00 |
| Mar 31, 2015 | 317,000.00 |
| Dec 31, 2014 | -128,000.00 |
| Sep 30, 2014 | -949,000.00 |
| Jun 30, 2014 | -248,000.00 |
| Mar 31, 2014 | 1.35 Mn |
| Dec 31, 2013 | -2.01 Mn |